The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.
"I regard Migraine Buddy as providing a novel way of gathering real world evidence about migraine treatment.”
At the 2021 Virtual American Headache Society (AHS) 63rd Annual Scientific Meeting, June 3-6, research conducted by Richard B. Lipton, MD, evaluated the real-world effectiveness of ubrogepant (Ubrelvy; AbbVie) when used with onabotulinumtoxinA (Botox; Allergan/AbbVie), with a monoclonal antibody, or with both, using data collected on the Migraine Buddy app. The investigators concluded that the entirely remote design, made possible by the app, provides a unique opportunity to continue to understand more about patients with migraine, especially in a COVID-19-pandemic setting.
The app, which has over 1 million users, allows communication to doctors, insurance companies, and employers, while assisting patients in understanding their triggers and symptoms. Lipton, professor and vice chair of neurology, Albert Einstein College of Medicine, and director, Montefiore Headache Center, noted that studying medical claims, conducting surveys, and performing real-world clinical trials that do not interfere with a patient’s daily life are the traditional ways researchers have collected real-world data.
In an interview with NeurologyLive, Lipton discussed how Migraine Buddy can help change the way clinical trials are conducted, with the potential to reach larger masses of patients with migraine.
For more coverage of AHS 2021, click here.